Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Rattus norvegicus | Renin | Starlite/ChEMBL | References |
Homo sapiens | renin | Starlite/ChEMBL | References |
Species | Potential target | Known druggable target | Length | Alignment span | Identity |
---|---|---|---|---|---|
Candida albicans | secretory aspartyl proteinase SAP10p, related to SAP9p | Renin | 402 aa | 344 aa | 21.8 % |
Drosophila melanogaster | CG31926 gene product from transcript CG31926-RB | Renin | 402 aa | 415 aa | 33.5 % |
Candida albicans | secretory aspartyl proteinase SAP6p | Renin | 402 aa | 341 aa | 24.9 % |
Neospora caninum | hypothetical protein | Renin | 402 aa | 324 aa | 29.6 % |
Plasmodium falciparum | plasmepsin X | renin | 406 aa | 352 aa | 26.4 % |
Toxoplasma gondii | aspartyl protease ASP3 | Renin | 402 aa | 324 aa | 29.9 % |
Plasmodium falciparum | plasmepsin IX | Renin | 402 aa | 438 aa | 25.3 % |
Plasmodium berghei | plasmepsin X | Renin | 402 aa | 329 aa | 29.8 % |
Plasmodium knowlesi | aspartyl protease, putative | Renin | 402 aa | 369 aa | 27.1 % |
Plasmodium berghei | plasmepsin VII | Renin | 402 aa | 360 aa | 27.2 % |
Plasmodium falciparum | plasmepsin X | Renin | 402 aa | 332 aa | 29.8 % |
Plasmodium falciparum | plasmepsin III | Renin | 402 aa | 345 aa | 29.9 % |
Schistosoma mansoni | memapsin-2 (A01 family) | Renin | 402 aa | 440 aa | 21.1 % |
Toxoplasma gondii | aspartyl protease | Renin | 402 aa | 417 aa | 28.5 % |
Babesia bovis | aspartyl protease, putative | Renin | 402 aa | 350 aa | 28.3 % |
Loa Loa (eye worm) | aspartic protease BmAsp-1 | Renin | 402 aa | 408 aa | 26.5 % |
Candida albicans | secretory aspartyl proteinase SAP5p | Renin | 402 aa | 354 aa | 24.6 % |
Candida albicans | secretory aspartyl proteinase SAP8p | Renin | 402 aa | 333 aa | 23.7 % |
Plasmodium knowlesi | eukaryotic aspartyl protease, putative | Renin | 402 aa | 328 aa | 28.7 % |
Onchocerca volvulus | Renin | 402 aa | 340 aa | 30.6 % | |
Candida albicans | secretory aspartyl proteinase SAP6p | Renin | 402 aa | 341 aa | 24.6 % |
Candida albicans | secretory aspartyl proteinase SAP4p | Renin | 402 aa | 341 aa | 24.3 % |
Plasmodium vivax | aspartyl protease, putative | Renin | 402 aa | 455 aa | 25.1 % |
Neospora caninum | Cathepsin D enzyme (EC 3.4.23.5), related | Renin | 402 aa | 358 aa | 30.4 % |
Candida albicans | secretory aspartyl proteinase SAP10p, related to SAP9p | Renin | 402 aa | 344 aa | 21.8 % |
Plasmodium vivax | aspartyl protease, putative | Renin | 402 aa | 385 aa | 27.8 % |
Candida albicans | secretory aspartyl proteinase SAP5p | Renin | 402 aa | 354 aa | 24.6 % |
Babesia bovis | aspartyl protease, putative | Renin | 402 aa | 333 aa | 25.8 % |
Plasmodium falciparum | plasmepsin VII | Renin | 402 aa | 367 aa | 24.3 % |
Plasmodium yoelii | Eukaryotic aspartyl protease, putative | Renin | 402 aa | 329 aa | 29.5 % |
Candida albicans | secretory aspartyl proteinase SAP8p | Renin | 402 aa | 333 aa | 23.7 % |
Onchocerca volvulus | Sphingomyelin phosphodiesterase 1 homolog | Renin | 402 aa | 414 aa | 40.3 % |
Candida albicans | secretory aspartyl proteinase SAP4p | Renin | 402 aa | 341 aa | 24.3 % |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
IC50 (binding) | = -6.82 | Inhibition of human plasma renin | ChEMBL. | 3316655 |
IC50 (binding) | = 0.000000015 M | Inhibition of hog man plasma renin activity | ChEMBL. | 3543358 |
IC50 (binding) | = 0.000000022 M | Inhibition of rat plasma renin activity | ChEMBL. | 3543358 |
IC50 (binding) | = 0.000000025 M | Inhibition of monkey plasma renin activity | ChEMBL. | 3543358 |
IC50 (binding) | = 0.000000042 M | Inhibition of dog plasma renin activity | ChEMBL. | 3543358 |
IC50 (binding) | = 0.00000015 M | In vitro inhibitory activity against human plasma renin | ChEMBL. | 3543358 |
IC50 (binding) | = 0.00000015 M | Inhibition of man plasma renin activity | ChEMBL. | 3543358 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
2 literature references were collected for this gene.